In particular, the use of cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1), and programmed cell death 1 ligand 1 (PD-L1) inhibitors in the clinic has become a landmark breakthrough in tumor immunotherapy [35]. This evidence concerns the gene CTLA4 and neoplasm.